All In Biotech

Drug Trial Radar · NCT04540211

A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Patients With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma

Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 461 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

461

Actual

Start

Oct 30, 2020

Primary completion

Feb 13, 2023

Study completion Aug 28, 2025

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Sep 7, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of atezolizumab plus tiragolumab in combination with paclitaxel and cisplatin (PC) compared with atezolizumab matching placebo plus tiragolumab matching placebo plus PC as first-line treatment in participants with unresectable locally advanced, unresectable recurrent, or metastatic esophageal carcinoma (EC). Participants will be randomized in a 1:1 ratio to receive one of the following treatment regimens during induction phase: Arm A: Atezolizumab plus Tiragolumab and PC Arm B: Atezolizumab placebo plus Tiragolumab placebo and PC Following the induction phase, participants will continue maintenance therapy with either atezolizumab plus tiragolumab (Arm A) or atezolizumab matching placebo plus tiragolumab matching placebo (Arm B).

Conditions

  • Esophageal Cancer

Interventions

  • AtezolizumabDrug

    Atezolizumab at a fixed dose of 1200 milligrams (mg) administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.

  • TiragolumabDrug

    Tiragolumab at a fixed dose of 600 mg administered by IV infusion every Q3W on Day 1 of each 21-day cycle.

  • PaclitaxelDrug

    Paclitaxel 175 mg/m\^2 administered by IV infusion on Day 1 of each 21-day cycle for 6 cycles.

  • CisplatinDrug

    Cisplatin 60-80 mg/m\^2 administered by IV infusion on Day 1 of each 21-day cycle for 6 cycles.

  • Atezolizumab Matching PlaceboDrug

    Atezolizumab matching placebo administered by IV infusion, Q3W on Day 1 of each 21-day cycle.

  • Tiragolumab Matching PlaceboDrug

    Tiragolumab matching placebo administered by IV infusion, Q3W on Day 1 of each 21-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Independent Review Facility (IRF)-Assessed Progression-free Survival (PFS)Time frame: From randomization to the first occurrence of PD or death from any cause, whichever occurred first (up to approximately 19 months)
  2. Overall Survival (OS)Time frame: From randomization to death from any cause (up to approximately 27.5 months)

Locations

67 sites in 5 countries. Site status is shown where the registry gives one.

  • Anhui Provincial Hospital

    Anhui, China

  • Anyang Tumor Hosptial

    Anyang, China

  • Beijing Luhe Hospital Capital Medical University

    Beijing, China

  • the First Hospital of Jilin University

    Changchun, China

  • Jilin Cancer Hospital

    Changchun, China

  • Hunan Cancer Hospital

    Changsha, China

  • Affiliated Hospital of Chengde Medical University

    Chengde, China

  • Sichuan Provincial Cancer Hospital

    Chengdu, China

  • West China Hospital, Sichuan University

    Chengdu, China

  • Chongqing Sanxia Central Hospital

    Chongqing, China

  • The First People's Hospital of Foshan

    Foshan, China

  • Fujian Cancer Hospital

    Fuzhou, China

  • Fujian Provincial Hospital

    Fuzhou, China

  • Southern Medical University Nanfang Hospital

    Guangdong Province Guangzhou City, China

  • Zhejiang Cancer Hospital

    Hangzhou, China

  • Harbin Medical University Cancer Hospital

    Harbin, China

  • Anhui Province Cancer Hospital

    Hefei, China

  • The Second Affiliated Hospital of Anhui Medical University

    Hefei, China

  • Huai'an First People's Hospital

    Huai'an, China

  • The Second People's Hospital of Huai'an

    Huai'an, China

  • Affiliated Hopsital of Jining Medical University

    Jining, China

  • Gansu Province People Hospital

    Lanzhou, China

  • The First People's Hospital of Lian Yun Gang

    Lianyungang, China

  • Linyishi Cancer Hospital

    Linyi, China

  • The First Affiliated Hospital to Henan University of Science and Technology

    Luoyang, China

  • Jiangsu Province Hospital of Chinese Medicine

    Nanjing, China

  • Jiangsu Cancer Hospital

    Nanjing, China

  • Nan Tong Tumor Hospital

    Nantong, China

  • Shanghai Chest Hospital

    Shanghai, China

  • Zhongshan Hospital Fudan University

    Shanghai, China

  • Fudan University Shanghai Cancer Center

    Shanghai, China

  • Cancer Hospital of Shantou University Medical College

    Shantou, China

  • Liaoning Provincial Cancer Hospital

    Shengyang, China

  • Suining Central Hospital

    Suining, China

  • Tianjin Cancer Hospital

    Tianjin, China

  • Weifang People's Hospital

    Weifang, China

  • Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, China

  • Hubei Cancer Hospital

    Wuhan, China

  • Affiliated Hospital of Jiangnan University(Wuxi Fourth People's Hospital )

    Wuxi, China

  • The Second Affiliated Hospital of The Fourth Military Medical University (Tangdu Hospital)

    Xi'an, China

Showing 40 of 67 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.